Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis. 2011;6:18.

Article  PubMed  PubMed Central  Google Scholar 

Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet. BMJ Publ Group Ltd. 1989;26:712–21.

CAS  Google Scholar 

Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell Elsevier. 1990;62:187–92.

Article  CAS  Google Scholar 

Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Sci Am Assoc Advancement Sci. 1990;249:181–6.

CAS  Google Scholar 

DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell Elsevier. 1992;69:265–73.

Article  CAS  Google Scholar 

Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman J-J, et al. TP53 mutations are frequent in malignant NFI tumors. Genes Chromosomes Cancer. 1994;10:250–5.

Article  CAS  PubMed  Google Scholar 

Rao UN, Sonmez-Alpan E, Michalopoulos GK. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol. 1997;28:1066–70.

Article  CAS  PubMed  Google Scholar 

Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res. 2008;14:1015–24.

Article  CAS  PubMed  Google Scholar 

Verdijk RM, den Bakker MA, Dubbink HJ, Hop WCJ, Dinjens WNM, Kros JM. TP53 mutation analysis of malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 2010;69:16–26.

Article  CAS  PubMed  Google Scholar 

Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 2011;17:1924–34.

Article  CAS  PubMed  Google Scholar 

De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nat Nat Publ Group. 2014;514:247–51.

Google Scholar 

Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. Nat Publ Group. 2017;7:14992.

Google Scholar 

Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22:443–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin E, Lamba N, Flucke UE, Verhoef C, Coert JH, Versleijen-Jonkers YMH, et al. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside. Crit Rev Oncol Hematol. 2019;138:223–32.

Article  PubMed  Google Scholar 

Natalie Wu LM, Lu QR. Therapeutic targets for malignant peripheral nerve sheath tumors. Future Neurol Future Med. 2019;14:FNL7.

Article  CAS  Google Scholar 

Staedtke V, Bai R-Y, Blakeley JO. Cancer of the Peripheral Nerve in Neurofibromatosis Type 1. Neurother J Am Soc Exp Neurother. 2017;14:298–306.

CAS  Google Scholar 

Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrari A, Bisogno G, Macaluso A, Casanova M, D’Angelo P, Pierani P, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007;109:1406–12.

Article  PubMed  Google Scholar 

Ferrari A, Miceli R, Rey A, Oberlin O, Orbach D, Brennan B, et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. Eur J Cancer Elsevier. 2011;47:724–31.

Article  Google Scholar 

Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors (MPNSTs). J Neurosurg. 2017;126:319–29.

Article  PubMed  Google Scholar 

Carroll SL. The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics. Am J Pathol Elsevier. 2016;186:464–77.

Article  CAS  Google Scholar 

Dong J, Li B, Lin D, Zhou Q, Huang D. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. Frontiers; 2019;10. https://www.frontiersin.org/articles/10.3389/fphar.2019.00230/full.

Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, et al. Malignant Peripheral Nerve Sheath Tumors. Oncologist. 2014;19:193–201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38:156.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grit JL, Pridgeon MG, Essenburg CJ, Wolfrum E, Madaj ZB, Turner L, et al. Kinome profiling of NF1-related MPNSTs in response to kinase inhibition and doxorubicin reveals therapeutic vulnerabilities. Genes. 2020;11:331.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suresh TN, Harendra Kumar ML, Prasad CSBR, Kalyani R, Borappa K. Malignant peripheral nerve sheath tumor with divergent differentiation. Indian J Pathol Microbiol. 2009;52:74–6.

Article  CAS  PubMed  Google Scholar 

Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, et al. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology 2016;87:S40–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, et al. Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Mod Pathol Nat Publ Group. 2018;31:1694–707.

Article  Google Scholar 

Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro-Oncol. 2009;11:514–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang W-L, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014–22.

Article  PubMed  Google Scholar 

Karpinsky G, Krawczyk MA, Izycka-Swieszewska E, Fatyga A, Budka A, Balwierz W, et al. Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol. 2018;144:519–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Torres KE, Zhu Q-S, Bill K, Lopez G, Ghadimi MP, Xie X, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res J Am Assoc Cancer Res. 2011;17:3943–55.

Article  CAS  Google Scholar 

Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19:450–61.

Article  CAS  PubMed  Google Scholar 

Peacock JD, Pridgeon MG, Tovar EA, Essenburg CJ, Bowman M, Madaj Z, et al. Genomic status of MET potentiates sensitivity to MET and MEK inhibition in NF1-related malignant peripheral nerve sheath tumors. Cancer Res. 2018;78:3672–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, et al. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of Schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014;5:1502–14.

Article  PubMed  PubMed Central  Google Scholar 

Bradtmöller M, Hartmann C, Zietsch J, Jäschke S, Mautner V-F, Kurtz A, et al. Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours. PLoS ONE. 2012;7:e47595.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro-Oncol. 2008;10:946–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui D, Qu R, Liu D, Xiong X, Liang T, Zhao Y. The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses. Front Cell Dev Biol. 2021;9. https://www.frontiersin.org/articles/10.3389/fcell.2021.775507.